Trials / Completed
CompletedNCT00406016
Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI
A Multi-center, Open-label, Cohort Study to Assess Feasibility, Acute Safety, Tolerability and Pharmacokinetics of 4 Dose Regimens of Continuous Intrathecal ATI355 Infusion and Two Regimen of Repeated Intrathecal Bolus Injections in Acute Spinal Cord Injury Paraplegic and Tetraplegic Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the acute safety, tolerability, feasibility and pharmacokinetics of 6 dose regimens of ATI355 in acute spinal cord injury patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATI355 |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2011-09-01
- Completion
- 2011-09-01
- First posted
- 2006-12-04
- Last updated
- 2020-02-11
Locations
14 sites across 3 countries: Canada, Germany, Switzerland
Source: ClinicalTrials.gov record NCT00406016. Inclusion in this directory is not an endorsement.